cefotaxime and Tibial-Fractures

Osteofibrous dysplasia is a rare and benign disease that originates from the tibia or fibula. The symptoms of osteofibrous dysplasia include painless enlargement and bowing of the tibia and pain occurring in the presence of pathological fracture. Herein a male infant who was admitted with redness and swelling on the right leg and diagnosed as pathological tibia fracture due to left tibia osteofibrous dysplasia on the third day of life was presented. To our knowledge, this is the earliest presentation of osteofibrous dysplasia with a pathological fracture in a neonate. Therefore, it must be suspected in neonatal bone fractures.

Topics: Amikacin; Anti-Bacterial Agents; Casts, Surgical; Cefotaxime; Clindamycin; Fibrous Dysplasia of Bone; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Sepsis; Tibia; Tibial Fractures; Treatment Outcome

A prospective randomized study of severe open tibial fractures (Type II and III) was performed. Individual fractures were randomized to treatment groups according to initial antibiotic therapy: One consisted of a first-generation cephalosporin, and the other consisted of a third-generation cephalosporin. Initial antibiotic therapy was given in all patients for 48 h and then specific antibiotic treatment was used as indicated by culture. The purpose of this study was to determine whether or not additional gram-negative coverage had an effect on the overall infection rate or the type of infection in severe open tibial fractures. Additional factors, such as the timing of bone grafts and soft tissue coverage, were evaluated in this study as well. Although there was no statistical difference in the rate of infection with the use of a first- versus a third-generation cephalosporin, there was a trend toward a decreased infection rate as well as toward less morbid infections with the use of a third-generation cephalosporin. The study also confirms that early bone graft should not be performed prior to 6 weeks post injury or after successful soft tissue coverage has been achieved. On the other hand, soft tissue coverage procedures should be performed at the earliest possible date to decrease the overall infection rate.

Topics: Adolescent; Adult; Bacterial Infections; Cefazolin; Cefotaxime; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Fracture Fixation, Internal; Fractures, Open; Humans; Male; Middle Aged; Prospective Studies; Random Allocation; Surgical Wound Infection; Tibial Fractures; Wound Healing

Topics: Bone Transplantation; Bronchiolitis Obliterans; Cefotaxime; Cephalosporins; Cephapirin; Dibekacin; Drug Therapy, Combination; Humans; Kanamycin; Lung; Male; Middle Aged; Pulmonary Fibrosis; Tibial Fractures